Biofrontera Net Income Over Time
| BFRI Stock | USD 0.78 0.03 4.20% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biofrontera Performance and Biofrontera Correlation. Biofrontera | Build AI portfolio with Biofrontera Stock |
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Biofrontera and related stocks such as Gelteq Limited Ordinary, ProPhase Labs, and Aytu BioScience Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GELS | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (648.9 K) | (3.4 M) | (3.5 M) | (3.5 M) | (6.6 M) | (6 M) | (5.7 M) |
| PRPH | (700 K) | (2.7 M) | (1.1 M) | 405 K | (7.8 M) | (3.6 M) | (2.9 M) | 41.8 M | (1.7 M) | (3.1 M) | (2.1 M) | 6.3 M | 18.5 M | (16.8 M) | (53.4 M) | (48 M) | (45.6 M) |
| AYTU | (49 K) | (59.7 K) | (57.3 K) | (5.6 M) | (7.7 M) | (28.2 M) | (22.5 M) | (10.2 M) | (47.2 M) | (13.6 M) | (58.3 M) | (108.8 M) | (17.1 M) | (15.8 M) | (13.6 M) | (12.2 M) | (12.8 M) |
| EVGN | 645 K | 645 K | (2.5 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (18.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (23.9 M) | (16.5 M) | (14.8 M) | (15.6 M) |
| DWTX | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.5 M) | (10.3 M) | (16 M) | (12.2 M) | (5.3 M) | (12.3 M) | (11.1 M) | (11.7 M) |
| SNSE | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (16.7 M) | (20.1 M) | (36.8 M) | (48.8 M) | (34.1 M) | (30.2 M) | (27.1 M) | (28.5 M) |
| TRIB | (3.4 M) | 15.6 M | 17.3 M | 10.3 M | 17.2 M | 21.8 M | (100.6 M) | (40.3 M) | 2.4 M | (4.1 M) | (6.4 M) | 875 K | (41 M) | (24 M) | (31.8 M) | (28.6 M) | (27.2 M) |
| COCP | (58.7 K) | (5.5 M) | (8 M) | (19.6 M) | (99 K) | (50.1 M) | (74.9 M) | (613 K) | (49 M) | (48.2 M) | (9.6 M) | (14.2 M) | (38.8 M) | (18 M) | (17.5 M) | (15.8 M) | (16.5 M) |
| IMNN | (1.9 M) | (23.2 M) | (26.6 M) | (8.3 M) | (25.5 M) | (22.5 M) | (22.1 M) | (20.4 M) | (11.9 M) | (16.9 M) | (21.5 M) | (20.8 M) | (35.9 M) | (19.5 M) | (18.6 M) | (16.8 M) | (17.6 M) |
| SBFM | (13.1 K) | (556.2 K) | (708 K) | (2.5 M) | (1.9 M) | (1.7 M) | (3.5 M) | (1 M) | (2.2 M) | (1.7 M) | (2.8 M) | (12.4 M) | (26.7 M) | (4.5 M) | (5.1 M) | (4.6 M) | (4.9 M) |
Biofrontera and related stocks such as Gelteq Limited Ordinary, ProPhase Labs, and Aytu BioScience Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Biofrontera financial statement analysis. It represents the amount of money remaining after all of Biofrontera operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Biofrontera | BFRI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 120 Presidential Way, |
| Exchange | NASDAQ Exchange |
USD 0.776
Check out Biofrontera Performance and Biofrontera Correlation. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Biofrontera technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.